PraXsyn Announces That Its Subsidiary, Mesa Pharmacy, is Now Licensed in Illinois and Wisconsin


PALO ALTO, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- PraXsyn Corporation (OTCQB:PAWS), is pleased to announce that its pharmacy license applications, in the great State of Illinois and America's Dairyland, Wisconsin, were just approved.

"We are extremely excited to add these 2 great states to our list of states where we can dispense or ship medications. Together, these states have the potential of rivaling California as an extremely lucrative market for PraXsyn's pain management creams," said Dan Wiesel, CEO of PraXsyn. "PraXsyn's strategy is to provide an alternative to oral pain medications throughout the United States, and Illinois is just the first step in our expansion."

Our goal at PraXsyn to is provide medical practitioners with products and services to help them help their patients. Our Mesa Pharmacy division currently provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek.

About PraXsyn, Inc.

PraXsyn, Inc. is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams in our compounding pharmacy, Mesa Pharmacy. These are geared toward patients suffering from long-term pain associated with work place related injuries.

For additional information go to

Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.

CONTACT: Company Contact:

Source: PraXsyn